Phase 4
18 Years
65 Years
18 Years
65 Years
Not Enrolling
Both
Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase.
Both
Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase.
Trial Information
Inclusion Criteria:
- Consecutive patients undergoing high-dose chemotherapy showing early release of
Troponin I
Exclusion Criteria:
- Contraindication to ACE-inhibitors
- On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention
Outcome Measure:
Incidence of chemotherapy-induced cardiotoxicity
Principal Investigator
Carlo M Cipolla, MD
Investigator Role:
Study Director
Investigator Affiliation:
European Institute of Oncology
Authority:
Italy: Ministry of Health
Study ID:
IEO S67/500
NCT ID:
NCT00292526
Start Date:
Completion Date:
Related Keywords:
- Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase.
- Chemotherapy-induced cardiotoxicity
- Troponin
- Heart failure
Name | Location |
|---|
